viewAdmedus Ltd

Admedus Ltd chairman acquires shares on market


Admedus Limited (ASX:AHZ) non executive chairman Wayne Paterson has acquired 30,000 shares on market at $0.56 per share.

This week Admedus released encouraging interim results from the Phase II clinical study for a Herpes Simplex Virus (HSV-2) therapeutic vaccine which showed a decrease in viral lesions in patients in the trial.

There was a 90% decrease in viral lesions and outbreaks in trial patients, in the monthly rate versus baseline.

No safety issues were noted in this cohort of patients which is the primary endpoint of the Phase II trial.

The company said the data remains blinded and therefore no definitive conclusions can be made but that an analysis of the unblinded data from these 20 study participants will be performed during Q3 2016.

This will include assessment of the immunological endpoints including T cell response, as well as clinical and virological data.


Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.


Quick facts: Admedus Ltd

Price: 0.09 AUD

Market: ASX
Market Cap: $53.18 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...



Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read